Mesoblast Limited (MESO): Price and Financial Metrics

Mesoblast Limited (MESO): $5.37

0.36 (-6.28%)

POWR Rating

Component Grades








MESO Price/Volume Stats

Current price $5.37 52-week high $10.24
Prev. close $5.73 52-week low $1.61
Day low $5.33 Volume 223,700
Day high $5.76 Avg. volume 1,981,423
50-day MA $2.99 Dividend yield N/A
200-day MA $3.41 Market Cap 612.56M

MESO Stock Price Chart Interactive Chart >

Mesoblast Limited (MESO) Company Bio

Mesoblast Ltd. has established a diverse portfolio of product candidates based on its proprietary allogeneic, off-the-shelf mesenchymal lineage cell-based technology, with multiple active Phase 3 clinical programs. Mesoblast's lead product candidates target major diseases with significant unmet medical needs despite existing therapies. These include chronic heart failure, chronic low back pain due to degenerative disc disease, and immune-mediated conditions such as acute graft versus host disease and biologic refractory rheumatoid arthritis. The company is based in Melbourne, Australia.

MESO Latest News Stream

Event/Time News Detail
Loading, please wait...

MESO Latest Social Stream

Loading social stream, please wait...

View Full MESO Social Stream

Latest MESO News From Around the Web

Below are the latest news stories about MESOBLAST LTD that investors may wish to consider to help them evaluate MESO as an investment opportunity.

5 Stocks to Ride the Santa Claus Rally

Mesoblast (MESO), Coinbase (COIN), Western Gas (WES), JAKKS Pacific (JAKK), and Brinker International (EAT) have the potential to outperform in the seven-day period.

Yahoo | December 21, 2023

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has filed for orphan drug designation (ODD) and rare pediatric disease designation (RPDD) with the United States Food and Drug Administration (FDA) for its allogeneic cell therapy Revascor® (rexlemestrocel-L) in the treatment of the congenital heart disease hypoplastic left heart syndrome (HLHS). The filings were b

Yahoo | November 26, 2023

Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug

Mesoblast (MESO) partners with Blood and Marrow Transplant Clinical Trials Network to develop a pivotal study on its lead candidate, Ryoncil, for acute graft versus host disease. The stock rises 11%.

Yahoo | November 23, 2023

Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), a body including centers responsible for approximately 80% of all US allogeneic BMTs, has entered into an agreement to develop a pivotal trial of Mesoblast’s lead product candidate Ryoncil® (remestemcel-L) in the treatment of adults with steroid-refrac

Yahoo | November 21, 2023

Most Shareholders Will Probably Find That The Compensation For Mesoblast Limited's (ASX:MSB) CEO Is Reasonable

Key Insights Mesoblast's Annual General Meeting to take place on 28th of November Salary of US$672.7k is part of CEO...

Yahoo | November 21, 2023

Read More 'MESO' Stories Here

MESO Price Returns

1-mo 120.99%
3-mo N/A
6-mo 125.63%
1-year -21.95%
3-year -70.17%
5-year -53.22%
YTD 144.09%
2023 -62.20%
2022 -39.38%
2021 -43.46%
2020 15.20%
2019 78.88%

Continue Researching MESO

Here are a few links from around the web to help you further your research on Mesoblast Ltd's stock as an investment opportunity:

Mesoblast Ltd (MESO) Stock Price | Nasdaq
Mesoblast Ltd (MESO) Stock Quote, History and News - Yahoo Finance
Mesoblast Ltd (MESO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!